SCHEMBL4866802

SCHEMBL4866802

Cc1ccc(-c2cc(CCCCN)on2)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NOTUM Q6P988 4/20 0.49
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
DRD2 P14416 8/20 0.43
DRD4 P21917 8/20 0.43
DRD3 P35462 8/20 0.43
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868141 0.84 NOTUM (0.68) NOTUMMAPTSMN1; SMN2RAB9ANPC1
SCHEMBL2898351 0.82 NOTUM (0.70) MEN1KMT2ANOTUMMAPTSMN1; SMN2
SCHEMBL20721701 0.80 NOTUM (0.53) MEN1KMT2ANOTUMMAPTSMN1; SMN2
SCHEMBL14058091 0.80 MEN1 (0.52) MEN1KMT2ANOTUMMAPTSMN1; SMN2
SCHEMBL18608896 0.77 MEN1 (0.56) MEN1KMT2ANOTUMMAPTSMN1; SMN2
SCHEMBL8576421 0.76 MEN1 (0.55) MEN1KMT2ANOTUMMAPTSMN1; SMN2
SCHEMBL8577207 0.76 NOTUM (0.70) MEN1KMT2ANOTUMMAPTSMN1; SMN2
SCHEMBL1221788 0.76 MEN1 (0.58) MEN1KMT2ANOTUMMAPTSMN1; SMN2
SCHEMBL1715043 0.75 MEN1 (0.51) MEN1KMT2ANOTUMMAPTSMN1; SMN2
SCHEMBL17978510 0.74 NOTUM (0.46) NOTUMMAPTSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
EP-1618119-A2 PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS CHIRON CORPORATION (US) 2006-01-25 EP disclosed
US-20050009764-A1 Pyridyl substituted ketolide antibiotics CHIRON CORPORATION (US) 2005-01-13 US disclosed
WO-2004096822-A2 PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS CHIRON CORPORATION (US) 2004-11-11 WO disclosed
US-6756359-B2 ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS CHIRON CORPORATION 2004-06-29 US disclosed
EP-1404693-A2 C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY CHIRON CORPORATION (US) 2004-04-07 EP disclosed
US-20030125266-A1 C12 Modified erythromycin macrolides and ketolides having antibacterial activity CHU DANIEL (US) 2003-07-03 US disclosed
WO-2003004509-A2 C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009764-A1 Pyridyl substituted ketolide antibiotics PKLR, KHK, PGD MEN1 3279/4885KMT2A 2250/4885NOTUM 1886/4885
US-20030125266-A1 C12 Modified erythromycin macrolides and ketolides having antibacterial activity MRPL21, CYP51A1, CEL MEN1 2935/4885KMT2A 1920/4885NOTUM 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.